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Introduction. Ventricular tachycardia (VT) is a common symptom in cardiac disorders of 
different etiology. Abnormalities of ion channels are attributed to mutations in the genes 
encoding the channel protein and cause altered function of channels, which can predispose to 
arrhythmias. Due to the high incidence of cardiovascular disorders in Kazakhstan, we enrolled a 
study cohort of 95 patients of different clinical phenotypes of cardiomyopathies, including DCM, 
idiopathic VT but also patients with myocardial infarction as a consequence of coronary heart 
disease. The common denominator among the three main groups was the occurrence of severe 
episodes of VT in all patients. Using targeted resequencing, we investigated 96 cardiomyopathy 
associated candidate-genes in this cohort with the aim to detect rare and common variations in 
these genes associated with VT molecular basis. 
Methods and results: We have enrolled 95 patients with sporadic (64/95) or familial (26/95) 
cardiomyopathies (DCM: 37.3%, idiopathic Ventricular Tachycardy (idVT): 38.9%, coronary 
heart disease with severe episodes of ventricular tachycardia: 24.2%, and others: 3%). Using 
a customized HaloPlex Target Enrichment System™ (Agilent Technologies Inc., Santa Clara, 
CA, US) 96 cardiomyopathy associated candidate-genes were sequenced and identified 173 
mutations previously associated with cardiomyopathies (disease-associated variants listed 
in the Human Genome Mutation Database; HGMD). On average, each patient carried >1.6 
mutations, irrespective of the initial clinical diagnosis. Furthermore, 215 private (unique) non-
synonymous variants were observed in the patient cohort. Prediction scores (f.e. MetaLR) of the 
private variants indicated high probability of disease association. Including the newly identified 
high-probability variants, each patient carried on average >4.8 genetic variants. Interestingly, 
there was no difference in the frequency of genetic variants between the CAD and the DCM 
subgroup of patients. 
Conclusion: Our study indicates that CAD patients carry an overlapping pattern of genetic 
variants as observed for DCM patients or other forms of inheritable cardiac disorders. Multiple 
genetic mutations and novel variants were observed for most of the patients, independent of 
initial clinical diagnosis. Because of the wide overlap of the pattern of genetic variants between 
CAD and DCM patients we have to assume a polygenic effect and a common molecular basis 
for CAD and DCM or challenge the causal relation of a multitude of genetic mutations. 
